1. Authors

Emmanuel Kulwa Bunuma¹ Lucy Ochola², and Andrew K Nyerere³

Affiliations

¹. Pan African University Institute of Basic Sciences, Technology and Innovation, Nairobi,

². Senior Research Scientist, Institute of Primate Research, Nairobi, Kenya.

³. Chairman-Department of Medical Microbiology College of Health Sciences, Jomo Kenyatta University of Agriculture and Technology Nairobi, Kenya.

2. A survey of influenza subtypes in olive baboons in selected areas in Kenya

3. Abstract

Background - Worldwide infections with influenza A viruses are associated with substantial illness and death among mammals and birds, in humans it accounts for 250,000 -500,000 deaths per year its continuous mutation in different hosts poses a threat that can result in the emergence of a novel virus with an ability to cause a widespread pandemic. Surveillance of Influenza A viral genome from diverse hosts and subtyping is critical in understanding of the antigenic shift and drift of the influenza virus especially in hosts that are closely related to human beings like the Non-Human Primates (NHPs), pigs and birds. This study therefore identified the influenza subtypes circulating in *Papio anubis* (Olive baboons) at the interface of human and NHPs in Kenya.

Methods-Fifty nasal swabs samples were collected from baboons from the colony at the Institute of Primate Research (IPR), these animals were originally collected from Olorbototo, Yatta, Aberdares, Movoloni and Laikipia. The nasal swabs were collected in viral transport media using sterile dacron swabs and stored at -80°C. In this study, samples were screened initially using real time RT-PCR- CDC protocol for influenza A virus detection that targets the matrix gene and twenty five were found to be positive.

Results-The proportion positive were as follows, Olorbototo (75%), Ngurumani (44%) Aberdares (43%), Mavoloni (37.5%), Yatta (14%), and Laikipia (9%). These samples were taken through conventional PCR to amplify the haemagglutinin, neuraminidase and the matrix genes and eight samples were successfully amplified and later sequenced through 24-capillaries ABI 3500 XL Genetic Analyzer. Upon BLAST of these sequences, influenza subtypes H1N1 and H3N2 were detected. It was observed that the subtypes in baboons were as follows Olorbototo H1N1, Yatta H3N2, Aberdares H3N2, Mavoloni H1N1, Ngurumani H1N1 and Laikipia H1N1. Upon further analysis, the influenza positive Olive baboons were found to have been reared in the colony at IPR colony for between 1-2 years and were in close contact with personnel.

Coclusion-Given the presence of H1N1 and H3N2 subtypes in baboons suggests that baboons can be naturally infected with seasonal endemic human influenza viruses, avian emerging pandemic or pandemic swine flu origin.

4. Key words

Non-human primates, Influenza type A in Baboons, Baboons- Human interface, Asymptomatic flu in captured baboon.

5. Introduction

Globally, influenza A virus infection is accompanied with significant sickness and death amongst mammals and birds (Karlsson et al. 2012), in humans it is responsible for up to 5 million severe cases and between 250 000 to 500 000 deaths worldwide per year (Who et al. 2009). The health of humans and animals is largely interlocked with 6 out of 10 emerging diseases originating from animals (Reperant et al. 2016). Many dynamics in relation to animals, environments and humans lead to the emergence of zoonotic diseases. The environments linked with pathogens and their reservoir hosts are continuously mutable and the rate of change is growing. The drivers of change include the transformation of farming practices, predominantly in the unindustrialized world, habitat obliteration; human invasion and climate change (Morens & Fauci 2013).

It is critical to assess and understand the influences of these changes on the interfaces between Influenza type A and their hosts, and amongst the host and other species, as well as other wildlife, livestock and humans (Fuller et al. 2013). Nonhuman primates, the closest living relatives of humans, are susceptible to other respiratory viruses like paramyxoviruses that cause respiratory disease in humans (Sasaki et al. 2013). These considerations prompted additional searches for species harboring novel influenza in baboons.

Mammals such as baboons are likely conduits for cross-species transmission of respiratory pathogens like influenza viruses because of their close and long-term contact with their owners, scientists, audiences, domestic animals, wild animals, and birds. (Fuller et al. 2013) Identifying the Influenza subtypes circulating in baboons at the interface of human to non-human primates was the aim of this study with the null hypothesis that the Kenyan baboons at the human-animal cannot be infected with Influenza virus.

6.0 Methods

6.1 Study site

The study was conducted on purposively wildlly caught baboons from Olorbototo (Ngurumani), Aberdares, Ngurumani, Omolon (Oldonyo sabuki), these baboons had stayed for 1-2 years at the Institute of Primate Research at the time of this study. Figure 1 shows the location of the sites where the animals were caught within Kenya.

6.2 Study design

This was a cross-sectional study carried out on fifty nasal swab samples collected purposively from wild caught Olive baboons (*Papio anubis*) kept in the colony at the Institute of Primate Research (IPR) (1°20'47.95"S, 36°42'51.13"E, Nairobi Kenya), where the presence and subtypes of influenza virus circulating in baboons from selected sites in Kenya was determined.

6.3 Ethics statement.

All procedures reported herein were performed in accordance with institutionally approved animal care and use protocols with reference number IERC/08/16 approved by the Institutional Scientific and Ethics review Committee of the Institute of Primate Research Kenya. The committee is guided by the institutional guidelines as well as the international regulations including those of WHO and Helsinki conventional on the humane treatment of animals for scientific purposes and GLP. (Appendix 1)

6.4 Clinical assessment of animals

Animals within the colony at IPR undergo physical examination daily. Information relating to physical and bio data collected are indicated in Appendices 3,4 and 5. These clinical assessments were compared to the available classical flu fever signs in human for host response variability between non-human primates to the response seen in humans.

6.5 Laboratory methods

6.5.1 RNA extraction from the viral nasal swabs samples

The virus RNA was extracted from the clinical nasal swabs of Baboons using the QIAamp® Viral RNA extraction kit (Qiagen, Germany) following the manufacturer's protocol. Briefly, 150µl of the viral transport media was added to 500µl of lysis buffer per tube and allowed to incubate at room temperature for 10 min to allow for the lysis.

A 500µl aliquot of ethanol was added and pulse vortex performed for 15s to give a homogeneous solution. A 650µl volume of the lysed solution was put to the spin columns and centrifuged at 8000 G for 1 minute and column placed in a clean collection tube. Then 500µl of Buffer AW1 was added to the spin column and centrifuged at 12000G for 1min in a Eppendorf 5415R centrifuge (Eppendorf AG, Barkhausenweg, Hamburg, Germany) and the column placed in a clean collection tube. Then the column was washed with 500µl of Buffer AW2 and centrifuged at 13,000 G for 3 min in a centrifuge.

Then finally spin column was positioned in a 1.5 ml micro centrifuge tube and 60µl of Buffer AVE added to the column and allowed to incubate at room temperature for 1 min. The column was then centrifuged at 8,000 G in the Eppendorf centrifuge at room temperature for 1 minute to the filtrate (RNA) then storage was done at -80°C.

6.5.2 Real time RT-PCR

Real-time PCR amplification and screening was performed on an ABI 7500 (Applied Biosystems, CA, USA) using the AgPath-ID one-step RT-PCR kit (Applied Biosystems, Foster City, CA, USA). The total 25µl reaction volume for each sample enclosed 5 µl of extracted RNA, 12.5 µl of AgPath Kit 2X buffer, 1 µl of AgPath 25X enzyme mix, 5 pmol of Taqman probe, 10 pmol of each of the forward and reverse primers, and 6 µl of RNase-free water. Each RNA sample was tested by sets of matrix gene (Conserved gene across the subtypes) primers. For sample screening reverse transcription was achieved at 50°C for 30 min and 95°C for 15 min. PCR was achieved after 45 cycles of denaturation at 94°C for 15s and annealing at 55°C for 30s and final extension at 68°C for 5minutes the cycle threshold ≤ 40 was interpreted as positive.

6.5.3 Conventional RT-PCR for genomic amplification

The RT-PCR was performed using Superscript II One-Step RT-PCR system Platinum™ /Taq mix (Invitrogen Corporation, NY, USA). The reaction mix was organized by mixing 12.5µl of the 2x reaction mix, 0.5µl of the forward primer (20µM), 0.5µl the reverse primer (20µM) primers details and source are shown on the appendix 2-, 1.0µl Superscript II RT/Platinum Taq mix and this mixture was then capped using 7.5µl of distilled water to make a total of 22µl. 7µl of the RNA template was then added making the individual reaction volume to 29µl. Thermocycling conditions were, 1 cycle of reverse transcription at 50°C for 30 min followed by an initial denaturation of 94°C for 2min. This was followed by 35 cycles of; denaturation at 94°C for 30s, annealing at 55°C for 30s and strand extension at 68°C for 1 min. Finally the reaction mixture was incubated at 68°C for 1min to allow for extension of recessed ends of the amplicons. A final pause was set at 70°C.

6.5.4 Visualization of the amplicons by Agarose Gel electrophoresis

The agarose prepared was 1% and was prepared in 1x TBE buffer. The solution was mixed by spinning gently and then heating in a microwave until all the agarose melted.

Cooling was done for a few min at room temperature and then the gel was added at the ratio of 400mls of gel to 5µl of Ethidium bromide. Then the gel liquid at 37°C was then poured into an

electrophoretic tank with a comb and left to set and solidify for 40 minutes at room temperature. The combs were then carefully removed. 5µl of the PCR samples were mixed with the 3µl of the blue orange gel loading dye (Invitrogen, NY, USA) and then loaded onto the wells. A 1kb DNA ladder marker (Invitrogen, NY, USA 10787-018) was loaded on the first lane of each of the wells. The tank was run at 60 volts for about 90 minutes. The gel was then visualized and observed on the Alpha Imager gel documentation system (Alpha Innotech, CA, USA).

6.5.5 Clean-up of PCR products using Exosap-IT

Removing the dNTPs and primers from PCR product was done. PCR tubes covering 10µl of the PCR products to be purified were shortly spun then 3 µl of the ExoSap-IT enzyme (U. S Biological, Swampscott, MA, USA) was added to each of the PCR tubes, then followed by a brief vortex for 10s. They were then spun for 30s. The PCR tubes were then placed into Thermal Cycler, and incubated for 30 min at 37°C. Then inactivation of the ExoSap-IT enzyme by incubation for fifteen minutes at 80 °C before storing the product at 4 °C.

6.5.6 Cycle sequencing of the purified PCR products

PCR amplicons including fluorescent-labeled dideoxy-chain terminators were created using an ABI BigDye Terminator version 3.1 cycle sequencing Kit (Applied Biosystems, Forster City, USA). The reaction mixture for both the forward and reverse reactions were organized by adding 2µl of BigDye to 2µl BigDye 5X buffer then finally by addition of 1µl (4µM) of the M13R/F primers and 3µl of distilled water to make a total volume of 8µl. This reaction mixture was then loaded into each annotated well on the 96-well plate followed by addition of 2µl of the purified PCR product. The plates were enclosed with a sealing mat and were vortexed briefly.

The PCR running conditions were 1 cycle of initial denaturation at 95 °C for 5 min, followed by 30 Cycles of denaturation at 95 °C for 15 s, annealing at 45 °C for 30 s and strand extension at 68 °C for 2 min and 30 s. This was followed by a final incubation at 68 °C for 3 min to allow for extension of settled ends of the amplicons before storing the product at 4 °C.

6.5.7 Purification of the cycle sequencing products using sephadex spin columns.

®Sigma Dry sephadex G-50 medium powder was loaded into unused clean wells of 96-well Column Loader (Millipore, MA, USA). The 96 well Multi-Screen®-HV Plate Millipore was then placed upside down on top of the column loader, and both the Multi-Screen Plate and the column loader were held together and upturned. The top of the Column loader was selected to release the

resin. Then 300µl of Milli-Q water was then added to each well encompassing sephadex to swell the resin and the setup allowed to incubate at room temperature for 3 hours .The Multiscreen HV plate was then placed on top of a standard 96-well micro plate and then was spun at 8000rpm for 5 min on an Eppendorf 5810R bench top centrifuge (Eppendorf, Hamburg, Germany) using a two-tray rotor to eliminate extra water from the columns.

Extra water was then castoff. The sequencing products were sensibly added to the centre of each Sephadex well. The 96-well plate with the excess water was replaced with a new 96-well microplate (USA Scientific, FL, USA), and centrifugation done at 910× g. for 5 min guaranteeing that approximately 10µl of product came through the column. Then, 10µl of Hi-Di™ Formamide (Forster City, CA, USA) was added to guarantee the sequencing fragments were upheld as single strands and to hydrate any dry (empty) wells to circumvent extinguishing the capillaries.

6.5.8 Genetic analyzer procedure

The filtered PCR products from samples PAN 3837,PAN3342,PAN3350,PAN 3340,PAN 3638,PAN 3630 , PAN 3201 and the Hi-Di in the 96 well plate were placed into 24-capillaries ABI 3500 XL Genetic Analyzer (Applied Biosystems). These were left to run and nucleotide sequences were obtained using the sequence analysis software (Applied Biosystems).

6.5.9 Contiguous assembly

To make contiguous nucleotide sequences from the reverse and forward sequence runs for each amplified segment from the Genetic Analyzer, the sequences were put into the contig assembly program (CAP) of DNA Baser Sequence Assembler v3 (Heracle BioSoft SRL Romania, <http://www.DnaBaser>) and the consensus sequences were generated for BALST at <https://blast.ncbi.nlm.nih.gov>.The sequences are shown at the appendix =

6.5.10. Similarity searches

To determine whether the obtained nucleotide sequences were similar to Influenza A sequences deposited in genomic databases Blastn was performed at <https://blast.ncbi.nlm.nih.gov>.

6.6 Biosafety measures taken

Biosafety Level (BSL) 3 cabinet was used with protective equipment's worn all the time when handling the samples which includes laboratory coat, gloves and face masks ,appropriate sample labelling ,washing hands before and after every laboratory work.

6.7 Limitations of the study

This study could not culture the untyped baboons influenza virus in avoidance of the risks that might have been associated with it, and hence this made very low nucleic acid materials available for different target gene amplifications. This factor also limited this study from doing serological tests as preliminary test and hence opted the real time PCR as the screening method as recommended by (WHO, 2012), limited time allocated for the study could not allow sampling of other species and hence data for avians and humans for this study are missing.

7.0 RESULTS

7.1 Real time Reverse Transcriptase PCR

Real time RT-PCR of the Matrix gene was used to screen fifty nasal swab samples collected from the colony. Of the fifty samples we found that 25 were positive by RT-PCR (on the appendix 7) it was reported that the colony baboons had stayed for 1-2 years at IPR. Results further indicated that majority of the positive animals were from Olorbototo (75%), Ngurumani (44%), Aberdares (43%), Mavoloni (37%), Yatta (14%) and Laikipia 9% (Table 1). This test was done in animals that ranged from 1–10 years of age at the time of sampling. Juvenile male baboons 1-4 years normally reach 5-7kgs in weight, while sub adult male 7-10 years reach 14-15kgs, juvenile female 3-4kgs and adult females reaches up to 13kgs. The results on the real time RT-PCR shows that juveniles are mostly infected compared to adults and sub-adults and that the total numbers of males infected were 11 and females were 12.

7.2 Amplification of the positive samples from real time rt-PCR

The RT-PCR one step for HA fragment amplification was done in PAN3837, PAN3342, PAN3350, PAN3315 nasal swabs samples whereas the NA fragment amplification was done in PAN 3340, PAN3338, PAN3640 and PAN3201, finally the NA fragment was successfully amplified in PAN3350 and PAN3315 and Matrix genes was successfully amplified in PAN3640 and PAN 3201. The reason for missing bands and lack of multiple amplification of samples were due to low volume of nucleic acid present and hence unable to culture unsubtyped novel influenza virus from the baboons, the bands obtained are displayed on gel photos (Figure 2 and 3). The image was observed on Alpha Imager.

7.3 Sequences similarity searching in the gene bank

To conclude whether the obtained nucleotide sequences from the Kenyan baboons were similar to other influenza sequences placed in genomic databases, a similarity search against sequences in the influenza virus resource was done using blastn (<http://blast.ncbi.nlm.nih.gov/>) (Appendix 8) which compares the query to the other sequences deposited in the Influenza genome database.

7.4 Clinical assessment of influenza positive *P. anubis*.

The age of the animals at the time of nasal swab collection was estimated to be between 1-10 years. Of these 80% of the animals were between 1-5 years of age and these were also positive for influenza infection. Using amplification for the matrix gene by real time RT –PCR it was found that the positive samples were from Olorbototo (75%), Ngurumani (44%) Aberdares (43%), Mavoloni (37%), Yatta (14%), and Laikipia 9%.

These samples were taken through one step RT-PCR and only eight samples gave bands, which were then run through the 24-capillaries ABI 3500 XL Genetic Analyzer for sequencing and gave the following subtypes in baboons from Olorbototo H1N1, Yatta H3N2, Aberdares H3N2, Mavoloni H1N1, Ngurumani H1N1 and Laikipia H1N1.

The clinical signs of these subtyped baboon influenza isolates were documented as per the clinical information forms attached on appendices 5, 6 and 7, and presented on Table 4.2 below .

8.0 Discussion

In Africa Non-Human Primates are widely distributed for example in Zambia Baboons and vervet monkeys live side by side with humans in game management areas and this situation often leads to high levels of human–baboon/monkey conflicts, in these settings, scientists have found Human

Parainfluenza type 3 from Humans in baboons,(Sasaki et al. 2013) .Human metapneumo virus in wild great apes in Rwanda (Sasaki et al. 2013). In Kenya, studies have shown the presence of influenza in dogs, but there is no data available on baboons yet there are found in large numbers and are widespread. Based on this, the baboons from a selected area in Kenya were screened to identify the influenza subtypes circulating in them.

Upon screening of fifty samples of the wildy caught colony kept baboons, 25 were found to be positive for the M-gene , of which 80% of the positive samples were from juvenile animals (1-5 years).These results are consisted with (Karlsson *et al.*,2012) who screened 48 non-human primates and found 14 positive animals , In 2005, Whittier *et al.* reported positive titers to influenza A and B viruses as part of a wider survey of seroprevalence of infectious agents in non-human primates .This shows that non-human primates are also infected by influenza virus.

Despite baboons being infected with influenza it was observed that they lack clinical signs, this was in agreement with earlier studies that observed the same that even though the viruses replicate well in the respiratory tract, animals do not generally develop any symptoms of disease (Margine *et al.*.,2014) contrary of what is seen in humans, normally accompanied with pneumonia acute respiratory failure and runny nose (Leslie et al., 2016) which is frequently complicated by bacterial co-infection This may suggest that baboons are either opportunistic hosts or infections with influenza viruses in baboons might exacerbate the development of other diseases such as active TB which they succumb to (Tarara *et al.*, 1985). Viral infections induces the type I interferon's which inhibits the interferon- γ mediated immune responses which works to inhibit the development of active Mycobacterium tuberculosis (De Paus *et al.*,2013).

Two subtypes H1N1and H3N2 were identified in this study after sequencing and blastn .The H5N1 and other subtypes from avian species were not found which might indicate there were no avian species contact flu transmission. These observations further confirm results from an earlier study where seasonal subtype H1N1 and H3N2 influenza A strains were detected in performing macaques at frequencies of in Cambodia (29.2%), Singapore (16.7%), Sulawesi (16.1%), Bangladesh (13.3%), and Java (6.0%). (Karlson *et al.*, 2013). This study observed the following subtypes in baboons from Olorbototo H1N1,Yatta H3N2, Aberdares H3N2, Mavoloni H1N1, Ngurumani H1N1 and Laikipia H1N1.

The presence of influenza infections H1H1 and H3N2 subtypes in non-humans primates in Kenya confirms that baboons can also be infected with Influenza virus nevertheless with non-

classical flu fever. Extra epidemiologic studies of humans and wild caught colony kept nonhuman primates are needed to determine whether Influenza virus is transmitted between humans and wild nonhuman primates or from other species like the porcine and avian.

8.1 Conclusion

Screening of nasal swabs by real-time reverse transcription PCR results indicated the presence of the conserved matrix gene which confirms the presence of influenza viruses in the baboons. Non-human primates can therefore naturally be infected with influenza viruses and the viruses replicate in the respiratory tract but without necessarily developing the clinical signs. This means that they can harbor viruses unnoticed if we only depend on clinical signs to diagnose. The subtype H1N1 and H3N2 influenza A strains were identified circulating in non-human primates. These two subtypes have also been identified in human, so further epidemiologic studies can be done to search how baboons affect the transmission of these viruses.

8.2 Recommendations

There is a need for continuous surveillance and monitoring of genetic changes and virus evolution in wild and domesticated animal populations for example bats, rodents, camels .Continuous surveillance would also be critical in identifying other influenza viruses circulating in these animal populations in Kenya. Assimilating this surveillance with on-going surveillance for influenza viruses in humans will provide useful information for public health action vaccines, novel flu virus.

8.3 Acknowledgements

This work was supported by the Africa Union – African innovation JICA – JKUAT and PAUSTI joint Project.

Competing interest

No competing interests were disclosed

Grant information

This work was funded by the African Union and the Japan International Cooperation Agency (JICA)

Acknowledgements

My sincerest gratitude to Prof. Wallace D. Bulimo from University of Nairobi who assisted in molecular analysis of this work.

References .

1. De Paus RA, Van Crevel R, Van Beek R, Sahiratmadja E, Alisjahbana B, Marzuki S, et al. The influence of influenza virus infections on the development of tuberculosis. *Tuberculosis*. 2013;93(3):338–42.
2. Duncan Mwangangi Matheka, Jolynne Mokaya, and Marybeth Maritim , Overview of influenza virus infections in Kenya_ past, present and future. 2013
3. Fuller TL, Gilbert M, Martin V, Cappelle J, Hosseini P, Njabo KY, et al. Predicting Hotspots for Influenza Virus Reassortment. 2013;19(4):581–8.
4. Identification and Characterization of Influenza A Viruses among Domestic Animals in Selected Sites in Kenya A thesis submitted in fulfillment of the requirements for Doctor of Philosophy degree of the University of Nairobi (Epidemiology) PENINAH MBAIRE. 2015;
5. Jong YA De, Butynski TM. DISTRIBUTION AND CONSERVATION OF THE PATAS MONKEY ERYTHROCEBUS PATAS IN KENYA. 2008;97(1):83–102.
6. Karlsson EA, Engel GA, Feeroz MM, San S, Rompis A, Lee BPY, et al. In fl uenza Virus Infection in Nonhuman Primates. 2012;18(10):1672–5.
7. Margine I, Krammer F. Animal Models for Influenza Viruses: Implications for Universal Vaccine Development. 2014;845–74.
8. Moncla LH, Ross TM, Dinis JM, Weinfurter JT, Mortimer TD, Schultz-darken N, et al. A Novel Nonhuman Primate Model for Influenza Transmission. 2013;8(11).
9. Morens DM, Fauci AS. Emerging Infectious Diseases□: Threats to Human Health and Global Stability. 2013;9(7):7–9.
9. Sasaki M, Ishii A, Orba Y, Thomas Y, Hang BM, Moonga L, et al. Parainfluenza Virus.

2013;19(9):1500–3.

10. WHO , Centre C, Atlanta CDC, States U. CDC protocol of realtime RTPCR for influenza A (H1N1) Characterization of Swine Influenza (version 2009) General Comments. 2009;1(April).
11. Reperant LA, Moesker FM, Osterhaus ADME. Influenza□: from zoonosis to pandemic. 2016;1–4. Available from: <http://dx.doi.org/10.1183/23120541.00013-2016>

9.0.Figures and Tables

Figure 1 Map of Kenya showing the sites where the animals originated from.

Figure2: Gel photo showing the PCR amplification of the three influenza gene (HA, NA, genes)

Segments. Lane 1, 1kb ladder marker, Lane 2, 3, 4, 5, is HA fragment for PAN3837, PAN3342, PAN3350, PAN3315 respectively , Lane 6 is negative control for HA ,Lane 7,8,9,10, is NA fragments for PAN 3340, PAN3338, PAN3640 and PAN3201 respectively, Lane 11 is negative control for NA.

Figure 3 Gel photo showing the PCR amplification of the three influenza gene (NA, and M genes)

Lane 1, 1kb ladder marker, Lane 2 and 4 are NA fragments for PAN3315 and PAN 3350 respectively and Lane 3 is the Negative control ,Lane 5 and 7 is MA fragment for PAN3640 and PAN 3201 respectively and lane 6 is the negative control.

Table 1: The results for the real time RT-PCR

Sample ID	CT Value	Area of collection	Sex	Weight	Age
PAN 3642	41.091	Olorbototo	M	16	6
PAN3637	40.513	Olorbototo	M	18	7
PAN 3837	38.1461	Yatta	F	12	5
PAN 3342	38.605	Olorbototo	F	9	4
PAN 3641	42.03	Olorbototo	M	19	6
PAN 3625	44.105	Olorbototo	F	14	5
PAN 3629	40.157	Olorbototo	F	15	6
PAN3188	41.20	Yatta	F	14	5
PAN 3340	38.099	Olorbototo	M	12	5
PAN3638	34.219	Olorbototo	M	9	4
PAN 5536	36	Yatta	M	16	6
PAN3630	37.1206	Aberdares	F	15	5
PAN 3201	38.9381	Olorbototo	F	10	5
PAN3484	44.032	Yatta	M	9	6
PAN 3585	42.502	Olorbototo	M	13	5
PAN 3315	37.1621	Mavoloni	M	11	6
PAN 3197	43.102	Olorbototo	F	10	4
PAN 3587	41.323	Olorbototo	F	9	5
PAN 3335	42.012	Olorbototo	M	19	6
PAN 3350	38.4184	Olorbototo	F	21	6
PAN 3632	40.371	Olorbototo	F	17	5
PAN 3647	35.9276	Olorbototo	F	14	4
PAN 3623	43.812	Olorbototo	F	11	6
PAN 3624	37.2694	Olorbototo	F	12	5
PAN 3464	44.353	Olorbototo	F	24	7
PAN 3613	39.5136	Aberdares	M	18	6
PAN 3459	40.323	Olorbototo	M	23	6

PAN 3181	38.8304	Aberdares	M	15	4
PAN 3540	37.157	Yatta	M	13	5
PAN 3560	45.392	Orbototo	F	16	6
PAN 3646	39.3754	Orbototo	M	17	5
PAN 3479	48.2390	Olorbototo	F	10	4
PAN 3334	37.7283	Aberdares	F	11	5
PAN 3538	47.293	Mavolani	F	9	4
PAN 3343	43.393	Orbototo	F	10	4
PAN 3339	38.3343	Mavolani	F	11	5
PAN 3186	38.5032	Mavoloni	F	12	5
PAN 3631	44.282	Mavoloni	M	13	4
PAN 3505	37.6242	Mavoloni	M	14	5
PAN 3621	43.4492	Yatta	M	15	4
PAN 3643	35.1316	Olorbototo	M	16	5
PAN 3837	37.4909	Laikipia	M	18	6
PAN3338	38.2143	Yatta	M	15	5
PAN 3640	38.5427	Ngurumani	F	13	4
PAN 3537	41.34334	Ngurumani	M	15	5
PAN 3634	46.325	Olorbototo	M	16	6
PAN 3201,	38.5026	Ngurumani	F	18	7
VE +	28.17				
VE _	_VE				

Table 1 The original location of *P. anubis* and percentage of influenza positive samples.

Location	No. of Baboons	Type(s)	No of positive (%)
Olorbototo	8	Colony	6(75)
Yatta	7	Colony	1(14)
Aberdares	7	Colony	3(43)
Mavoloni	8	Colony	3(37.5)
Ngurumani	9	Colony	4(44)
Laikipia	11	Colony	1(9)

Table 3 Clinical symptoms of baboons found to be positive with influenza A but yet they didn't present the clinical influenza fever symptoms

Sample ID	Clinical information of the sampled Baboons
PAN3837	Thin, skin wounds on thighs and Respiratory system normal
PAN3201	Strongyloides species eggs, enlarged auxiliary inguinal nodes with respiratory system normal.
PAN3638	Cysts of Entamoeba were identified, alopecia on hind limbs with respiratory system normal.
PAN3350	Eggs of Trichuristrichura and Strongyloides, alopecic all over the body, with Respiratory system normal.
PAN3315	Was pregnant, cysts of Entamoeba and had a Normal respiratory system
PAN3340	Thin ,alopecic on thighs with normal respiratory system Eosinophilia, irregular Heart rates, with Inguinal lymph node swollen and Respiratory system normal
PAN3342	Had normal respiratory system, with swollen auxiliary lymph node
PAN3630	Had eggs of Strongyloides and alopecic on the lumber area.

Partial sequences of the positive influenza nasal swabs isolates

>1 H1N1 2016 Isolates from Baboons PAN 3837

TTATTTTTTTTTTTTGTCTCAGGGAGCAAAAGCAGGGGTCAGGATATGCAGCCGATCT
GAAGAGCACACAAAATGCCATCGATAAGATTACTAACAAAGTAAATTCTGTTATTGA
AAAGATGAATACACAGTTCACAGCAGTGGGTAAAGAGTTCAACCACCTTGAAAAAAG
AATAGAGAATCTAAATAAAAAAGTTGATGATGGTTTCCTGGACATTTGGACTTACAAT
GCCGAAGTGTGGTTCTACTGGAAAATGAAAGAAATTTGGACTATCACGATTCAAATG
TGAAGAACTTGTATGAAAAAGTAAGAAACCAGTTAAAAACAATGCCAAGGAAATTG
GAAACGGCTGCTTTGAATTTTACCACAAATGCGATAACACATGCATGGAAAGTGTCAA
GAATGGGACTTATGACTACCCAAAATACTCAGAGGAAGCAAAATTAAACAGAGAAAA
AATAGATGGAGTAAAGCTGGAATCAACAAGGATCTACCATATTTTTTCGTCTCAGGGAG
CAAAAGCAGGGGGACATAGTGTGGTAATGAAACGAAAACGGGACTCTAGCA
TACTTACTGACAGCCAGACAGCGACCAAAAGAATTTGGGATGGCCATCAAATAGTGT
ACGTTACTTTGTGA

Similar to Influenza A virus (A/Shimoga/MCVRAG4823/2017(H1N1)(H1N1)) segment 4 hemagglutinin (HA) gene, partial cds.

>2 H1N1 2016 Isolates from Baboons PAN 3350

ATAATAAAGTCTCTGTGTTGAGGAATGTGCATCCTCAACATCCTCGGGCT
CCTGCTTTTGCTCCCGGAGACGAATAAACCACAAAAGGATATGCTGCTCC
CGTAGTCCAGATTGTGTTCTCTTCGGGTCGTCCTCTTATTAGTTCAACC
CAGAAGCAAGGTCTTATACAATCCAGCCCTGTTAGTTCTGGATGCTGAAC
AAAACCTCCTGCTTTTGCTCCCTGAGACCAATAATACTACGATATCTTGCT
TTATTGAGAATTTATTGTCAGTCCCAGTCCATCCATTCCGGATCCCAAATC
ATCTCAAAACCTTTTCTTGAACATAATGCTCTTAGTTCTCCCTATCCAAAC
ACCATTGCCGTATTTGAATGAAAATCCTTTTACTCCTGCTTTTGCTCCCT
GAAACCAATATAAA

Similar to Influenza A virus (A/Pennsylvania/56/2018(H1N1)) segment 6 neuraminidase (NA) gene, complete cds

>3 H3N2 2016 Isolates from Baboons PAN 3340

TTCCAAAAAGCGCAGGAGCATATATAAGCGTGACATTGGCGTCCCCCCCCA
TCGGGCCGTGCCTCTGTTCTTCTGTCCCTGAAGTGCCACAACTCAAGA
TTTCTGTTTGAGGTCCACAAGTTTTCTTTTTCTTCTTCCCCTAAT
CAACTCAACATAAAAGCACCGATTGATGCATTTTTTGCCTTCAACAGAAA
AAATACCAAAATACCCGGACCTATCAAGAGGGAAATTTGTGAGAAGAATC
ATATTGTGAAATTGGAGAGAGAAACAGACCCAATCGTTTTTATCTTTTGA
TTGGGATTTCATCTTTACCCCTGTTTTTGCCCCCAGAGAAAAAAAACACA
CGTCTTTTCCATCATCAAATGCCACCCCTTTCCTCCTTGAACCCCTTCT
TCATTGATAAAATAAAAACAATGACTACTGCTGGAGCTGTCTTTTTTTTCG
GGGTGTGTCTCCAACAAGCCCTGAACACACATAACGGAAAACAATGCTAT
GACCCTTTATGTTTATATCTACTAGGGGCCGATTGGATCCTTTCCATTG
TCTCTGCAAACACCTCTGACACCGGGATATCGGGGATAGAAAGAGCTCTC
TTCCACATGCTGAGCACTTCCTGACTATGTGCTAGTATAAAAAATTCTCC
CCTCCTCAGAGAATAATTTTATAGTATCAGCTTTTCCTGTGGCTTTTCTA
TCAGTCTTCTCTACTGTACAATTACTATTGATACAAACGCTTTCAGACTC
CTGGTTTCGTGATCATCTCTTGAAAACGATGAAAAAAACACTATCACAAA
CT

Similar to Influenza A virus (A/Kenya/001/2017(H3N2)) segment 6 neuraminidase (NA) gene, complete cds

>4 H1N1 2016 Isolates from Baboons PAN 3315

AAAAGTTCGACACTAATTGATGGCCATCCGAATTCTTTTGGTCGCTGTCT
GGCTGTCAGTAAGTATGCTACAGTCCCGTTTTTCGTTTCATTACCAACACT
ATGTCCCCCTGCTTTTGCTCCCTGAGACGAAAAATCTGGTAGATCCTTGT
TGATTCCAGCTTTACTCCATCTATTTTTTCTCTGTTTAATTTTGCTTCCT
CTGAGTATTTTGGGTAGTCATAAGTCCCATTCTTGACACTTTCCATGCAT
GTGTTATCGCATTTGTGGTAAAATTCAAAGCAGCCGTTTCCAATTTCTT
GGCATTGTTTTTTAACTGGTTTCTTACTTTTTCATACAAGTTCTTCACAT
TTGAATCGTGATAGTCCAAATTTCTTTTCATTTTCCAGTAGAACCAACAGT
TCGGCATTGTAAGTCCAAATGTCCAGGAAACCATCATCAACTTTTTTATT

TAGATTCTCTATTCTTTTTTCAAGGTGGTTGAACTCTTTACCCACTGCTG
TGAAGTGTGTATTCATCTTTTCAATAACAGAATTTACTTTGTTAGTAATC
TTATCGATGGCATTCTTGTGTGCTCTTCAGATCGGCTGCATATCCTGACCC
CTGCTTTTGCTCCCTGAGAACGAAAAAAAAAAAAA

Similar to Influenza A virus (A/Shimoga/MCVRAG4823/2017(H1N1)(H1N1)) segment 4
hemagglutinin (HA) gene, partial cds

>5 H3N2 2016 Isolates from Baboons PAN 3630

CTCAAGTTGCGAAGGCTTATATAAGCCTGACATTGACGTCCGCCCCATCA
GGCCATGACCCTGTTCCATCTGTACCTGAAGTGCCACGAACCACAAGATT
ACGGTTTGAGGTCCACAAGACTTCAGTTTCCTCTTTTCTTCCCCTAATCA
ACTCAACATAAAAGCACCGATTGATGCAGCTTTTGCCTTCAACAGAGAAA
ATACCAGAATAACCGGACCTATCAAGATGGCAATTTGCATGAAGAAGCAT
ATTGTGGAAATGGTGAGAGAAACAGAGCCAATCGTTATTATCTTTTGATT
TGGATTTCATCTTTACTCCTGCTTTTGCTCCCTGAGACCAATAACCACACG
TCATTTCCATCATCAAATGCCAGCCTTTCACTCCATGAACACCTTCTTC
ATTGTTAGAATTCAAACAATGACTACTGCTGGAGCTGTCGTTTTTTCTGG
GTGTGTCTCCAACAAGTCCTGAACACACATAACTGGAAACAATGCTATGA
TCCTTTATGTTTATATCTACTATGGGCCGATTGGATCCTTTCCAGTTGTC
TCTGCAGACACATCTGACACCAGGATATCGAGGATAGCAAGAGCACTCTT
CGACATGCTGAGCACTTCCTGACAATTTGCTAGTATGAACGATTTTCCCC
TCCTCAATGAATAGTATTTTAGTATCAGCTTTTCCTGTAGCATTTCATC
AGTCATTACTACTGTACAAGTTCCATTGATACAAACGCATTCTGACTCCT
GGGTCCTGAGATATCTTTTGGAAACATGAAAAACACTATCTACAAGCCTCC
CATTGTAAATGAAGCTAGCAGTTGCATTTTATCATCCCCTGTTATACAA
ACATGCAGCCATGCTTTTCATCGTGACAACTTGAGCTAGGACCAAGGCTA
TTGCAACTGCCTGATCCAGAAATGGGAAGGAAACGCACCGAAGCACGACG
CTGCTGCTTGACGTA

Similar to Influenza A virus (A/Victoria/146/2016(H3N2)) neuraminidase (NA) gene, complete
cds

>6 H3N2 2016 Isolates from Baboons PAN 3342

CTTCTCCTTACTGGCATCCTTCCACAGCCAGAAGATTCGAGCAGAGAACTTGATGAGT
 ACTTGGCCTGGTATAACGACAGATCTTGAAGACTCTCGATGGAAGTACATGCAAGAC
 AAGATCAACTCTAGTCATCCTTCGACTTACGGGGATTTTATGGCCTGTTTTACGGCTC
 ACCGTGCCCAGTGAGCGAGGAGTGCAGCGTAGACTCCTTCGTCCAAAATGCCCTCAAT
 GGAATGGAGACCCAAATAACATGGACAAAGCAGTTCAAAGTGTATAGGAACTTAA
 GAGGGAGATAACGTTCCACGGGGCCAAAGAAATAGCTCTTAGTTATTCTGCTGGTGCA
 CTTGCCAGTTGCATGGGCCTCATATACAATAGGATGGGAGCTGTAACCACTGAAGTGG
 CATTTGGCCTGGTGTGTGCAACATGTGAGCAGATTGCTGATTCCCAGCACAGGTCTCA
 TAGGCAGATGGTGGCAACAACCAATCCATTAATAAAACATGAGAACAGAATGGTCTT
 GGCCAGCACTACAGCTAAGGCTTTGGTTATCCGTGTCAGGGAGCAAAAGCAGGTAGC
 GGAGGCCATGGAGATTGCTAGTCAGGCCAGGCAGATGGTGCAGGCAATGAGAGCCAT
 TGGGACTTATCCGAGTCAGGGAGCAAAAGCAAGAGATGATTTTAAAGAAAAGATGCA
 GTCCTATAAGAAATGAACGGGGGTGCAGTTGCAACGATTCAAAAAGCCCGGATGTTG
 TTGCCGGGAAATTCAATGGGATCTTGCACTCAGGCTTTTAGGGACAAACTCGAACCTT
 GTCCCATTTGATCTATGGACTCTTCAAACACGGCCGAGGAAGACGCCCTTAATGAGACG
 GGGGTCTTCTCAATGGGTGGAAGTTCAAATCATTCAACACCCAACATTTAAAATGTCA
 AGCACAAAATCATGTAGCAGACGATCAGTTTCT

Similar to Influenza A virus (A/Kenya/027/2017(H3N2)) segment 7 matrix protein 2 (M2) and matrix protein 1 (M1) genes, complete cds

>7 H3N2 2016 Isolates from Baboons PAN 3201

TGTATACATGTTATCTTTTCGCATCGTCATCAGACTCTCATGCCGAGATCGAGCAGAGA
 CTTGCAGATGTACTTTGCTTGGTATAACACAGATCCTGAGGCTCTCATGATGACTGAG
 ACAAGACCAATCTGTACCTTTGACTAAGGGATTTAGGGTTTGTTTTACGCTCACCGT
 GCCCAGTGAGCGAGGAGTGCAGCGTAGACGCTTTGTCCAAAATGCCCTCAATGGGAA
 TGGAGACCCAAATAACATGGACAAAGCAGTTAAAGTGTATAGGAACTTAAGAGGGA
 GATAACGTTCCACGGGGCCAAAGAAATAGCTCTTAGTTATTCTGCTGGTGCACCTTGCC
 AGTTGCATGGGCCTCATATACAATAGGATGGGAGCTGTAACCACTGAAGTGGCATTG

GCCTGGTGTGTGCAACATGTGAGCAGATTGCTGATTCCCAGCACAGGTCTCATAGGCA
 GATGGTGGCAACAACCAATCCATTAATAAAACATGAGAACAGAATGGTCTTGGCCAG
 CACTACAGCTAAGGCTATGGTTCTAAGTGTGAGGGAACAAAAGCAGGTAGCGGAGGC
 CATGGAGATTGCTAGTCAGGCCAGGCAGATGGTGCAGGCAATGAGAGCCATTGGGAC
 TTATCCGAGTTCCGGAGCAAAAGCAAGAGATGATTTTAAAGAAAATATGCAGACCTA
 TCAGAAATGAACGGGGGTGCAGATGCAACGATTCAAGTGACCCGGATGTTGTTGCCG
 GGAAAATCAATGGGATCTTGCCTCGAGCTTGTGGATTCAAATCGTCTCCTTGTCCA
 ATGGATCTATGGACTCTTCAAACACGGCCGAGGAGACGCCCTTAATGGGCCGGAGGA
 CCTCTCAAAGGAGGGAAGAATAACTCAAGCAACACCCAACATTTAAATGTCAAGCC
 CAAAATCATGTAGCAGACGTCCTGTACCT

Similar to Influenza A virus (A/Florida/02/2018(H3N2)) segment 7 matrix protein 2 (M2) and matrix protein 1 (M1) genes, complete cds

>8 (H1N1) 2016 Isolates from Baboons PAN3638

ATGCAAGGGTTGCGAAAACACACATGATCTCTTTGTTATACTAACACATT
 ATAGACATAGTAAATTCTGTTATTGAAAAGATGAATACACAGTTCACAGC
 AGTGGGTAAAGAGTTCAACCACCTTGAAAAAAGAATAGAGAATCTAAATA
 AAAAAGTTGATGATGGTTTCCTGGACATTTGGACTTACAATGCCGAAGTG
 TTGGTTCTACTGGAAAATGAAAGAACTTTGGACTATCACGATTCAAATGT
 GAAGAACTTGTATGAAAAAGTAAGAAACCAGTTAAAAACAATGCCAAGG
 AAATTGGAAACGGCTGCTTTGAATTTTACCACAAATGCGATAACACATGC
 ATGGAAAGTGTCAAGAATGGGACTTATGACTACCCAAAATACTCAGAGGA
 AGCAAAATTAAACAGAGAAAAAATAGATGGAGTAAAGCTGGAATCAACAA
 GGATCTACCAGATTTTGGCGATCTATTCAACTGTCGCCAGTTCATTGGTA
 CTGGTAGTCTCCCTGGGGGCAATCAGCTTCTGGATGTGCTCTAATGGGTC
 TCTACAGTGTAGAATATGTATTTAACATTAGGATTTTCAAGATCATGAGAA
 AAACACCCTTGTTTCTACTAATACGAGACAGATAATAGATAATAA

Similar to Influenza A virus (A/Vacaria/LACENRS-1312/2016(H1N1)) segment 4 hemagglutinin (HA) gene, complete cds

Appendix 1: Ethical approval for the study.

Institute of Primate Research

Address: P.O. Box 24481-00502 Karen Nairobi Kenya | Tel: +254 02 2606235 | Fax: +254 02 2606231
 URL: www.primateresearch.org | Email: directoripr@primateresearch.org

WHERE HERITAGE LIVES ON

P.O BOX 24481, KAREN, NAIROBI
 TELEPHONE 254-20-882571/4
 FAX: 254-20-882546
 E-Mail: irc@primateresearch.org

**INSTITUTIONAL SCIENTIFIC AND ETHICS REVIEW COMMITTEE
 (ISERC)**

FINAL PROPOSAL APPROVAL FORM

Our ref: IERC/08/16

Dear Dr. Joseph Kamau,

It is my pleasure to inform you that your proposal entitled "PREDICT/KENYA-KENYA WILDLIFE AND DOMESTIC CAMEL SERVEILLANCE FOR EMERGING PATHOGENS" in collaboration with Dr. Suzan Murray, Dr. Kali Holder, Dr. Dawn Zimmerman and Dr. Devin Tunsoth of the Smithsonian Institution, United States of America, Dr. Atunga Nyagieo and Dr. Daniel Chai of IPR, Kenya has been reviewed by the Institutional Review Committee (IRC) at a meeting of 28th June 2016. The proposal was reviewed on the scientific merit and ethical considerations on the use of animals for research purposes. The committee is guided by the Institutional guidelines as well as International regulations, including those of WHO, NIH, PVEN and Helsinki Convention on the humane treatment of animals for scientific purposes and GLP.

You are bound by the IPR Intellectual Property Policy.

Signed *Dr. I. Karani* Chairman IRC: *Dr. I. Karani*
20/7/2016.

Secretary IRC: *Dr. Ngalla Jillani*

Appendix 2: Primers used in this study

MATRIX GENE PRIMERS				
Gene fragment	Primer	Sequence	SKU	Qty
M	Fp	TATCCGTCAGGGAGCAAAAGCAGGTAGT C	1062901	29
	Rp	ATATCGTCTCGTATTAGTAGAAACAAGG TAGTTTTT	1062901	36
HA GENE PRIMERS				
Gene fragment	Primer	Sequence		Qty
HA	Fp	TATTCGTCTCAGGGAGCAAAAGCAGGGG		28
	Rp	ATATCGTCTCGTATTAGTAGAAACAAGG GTGTTTT		35
Gene fragment	Primer	Sequence		Qty
NA	Fp	TATTGGTCTCAGGGAGCAAAAGCAGGAG T		28

Rp ATATGGTCTCGTATTAGTAGAAACAAGG
AGTTTTTT

35

Appendix 3

Physical examination forms

INSTITUTE OF PRIMATE RESEARCH	
PHYSICAL EXAM	
Animal No. _____ Sex _____ Age _____ Yr _____ Mo. _____ () Actual () Estimated	
Cage No. _____ Generation (F0, F1, F2, etc) _____ Origin: () IPR () Trapped () Purchased	
Reason for Physical Exam: () Routine health care () Pre-shipment () Experimental	
() Quarantine screening () Other _____ Requested by: _____ Project: _____	
General Condition: () Excellent () Good () Fair () Poor Current wt. _____ Kg	
Check : N = Normal, A = Abnormal	
SYSTEMS	
1. Digestive(upper)	
Teeth: () N () A	
Occlusion () N () A	
Gingiva: () N () A	
Calculi: () Present () Absent	
Missing teeth:	
Digestive (Lower): () N () A	
2. Respiratory: () N () A	
3. Circulatory: () N () A	
4. Hemo/Lymph: () N () A	
Lymph nodes: () N () A	
Spleen: () N () A	
5. Integument:	
Skin : () N () A	
Hair Coat : () N () A	
6. Musc/Skel:	
() Thin () Obese	
7. Nervous: () N () A () Not examined	
8. Special Senses: Eyes () N () A	
() Ophthalmoscopic exam performed	
9. Urinary: () N () A	
10. Reproductive - Male	
Testicles : () N () A	
Sperm : () N () A () Not examined	
11. Reproductive - Female	
A. Uterus : () N () A	
Pregnant : () Yes () No () ?	
Shape : Size: _____ mm	
() Pear	
() Globoid	
() Irregular	
Tone : () Flaccid () Soft () Firm () Hard () Other	
B. Cervix : () N () A	
C. Vulva/Vagina: () N () A () Not examined	
D. Ovaries: () N () A () Not palpated	
E. Nipples: () N () A	
Laboratory samples (taken at exam) : () CBC () PCV + P.P. () Clinical chemistry () Serum () Urinalysis () Rental culture () Stool sample () Other _____	
Additional comments: Indicate number of system involved; include all systems checked abnormal	
Examiner _____	
Date _____	

Appendix 4: Parasitology information form

INSTITUTE OF PRIMATE RESEARCH NATIONAL MUSEUMS OF KENYA PATHOLOGY AND DIAGNOSTICS, ANIMAL SCIENCES DEPARTMENT <small>P.O. Box 24481 - 00502, Karen, Nairobi. Tel: 020 - 2606235/6, Fax No. 020 - 2606231</small>									
PARASITOLOGY	FACILITY:	SEX:	ANIMAL IDENTITY						
	CAGE:	AGE:		SPECIES		NUMBER			
INVESTIGATOR	PROJECT:	WEIGHT Kg	DATE	DAY	MONTH	YEAR			
REQUESTED BY:			☐ Routine preventive health ☐ Experimental protocol or health care due to experimental protocol. Charge to Grant:						
CLINICAL HISTORY:			SPECIMEN:						
Post R.: Yes ☐ No ☐		Drug/Dosage used:							
Other:									
ANIMALS	Sex: ☐ F ☐ M	Generation: ☐ F ₀ ☐ F ₁ ☐ F ₂	Facility:						
For laboratory use only									
SPECIMEN DESCRIPTION									
DIRECT SALINE PREPARATION FINDINGS									
FORMOL-ETHER CONCENTRATION FINDINGS									
Reported by:				Date:					
DIAGNOSIS									
Diagnosis by:				Date:					
COPIES TO BE SENT <div style="display: flex; justify-content: space-between;"> ANIMAL'S FILE REQUESTOR ISO 9001: 2008 Certified LABORATORY FILE </div>									

Appendix 5 : Acquisition of the animal forms for vital events

INSTITUTE OF PRIMATE RESEARCH

VITAL EVENTS - ACQUISITION

Acquisition Type:-

() PD: Purchased/Donated

() TD: Trapped by IPR

() CB: Colony Born

Animal No: _____

Sp. No.

Sex: _____

Area/Cage: _____

Delivery Type:

() V: Vaginal

() N: Nonvaginal

() A: Foetus at Necropsy

Gen: _____

Age: _____

Yrs. Mos. A/E

Acquisition Date: _____

Day Mon Yr

Mother No: _____

Sp. No.

Father No: _____

Sp. No.

Geographic Origin: _____